Manh-Cuong Vo
Overview
Explore the profile of Manh-Cuong Vo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vo M, Nguyen V, Tran V, Oh H, Jung S, Bae W, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):143.
PMID: 40056167
Despite an initial response to platinum-based chemotherapy, most patients with extensive stage of small cell lung cancer (SCLC) have a poor prognosis due to recurrence. Additionally, the benefit of immune...
2.
Vo M, Jung S, Nguyen V, Tran V, Ruzimurodov N, Kim S, et al.
Heliyon
. 2024 Mar;
10(6):e27892.
PMID: 38524535
Despite major advances in therapeutic platforms, most patients with multiple myeloma (MM) eventually relapse and succumb to the disease. Among the novel therapeutic options developed over the past decade, genetically...
3.
Jung E, Chu T, Kim S, Vo M, Nguyen V, Lee K, et al.
Cytotherapy
. 2023 Dec;
26(3):242-251.
PMID: 38142382
Background Aims: Natural killer (NK) cell-based cancer immunotherapy is effective when combined with other treatment modalities such as irradiation and chemotherapy. NK cell's antitumor function to treat solid tumor, including...
4.
Vu S, Pham H, Pham T, Le T, Vo M, Jung S, et al.
Front Oncol
. 2023 Nov;
13:1275076.
PMID: 38023191
Major advances in the treatment of multiple myeloma (MM) have been achieved by effective new agents such as proteasome inhibitors, immunomodulatory drugs, or monoclonal antibodies. Despite significant progress, MM remains...
5.
Lakshmi Thangaraj J, Jung S, Vo M, Chu T, Phan M, Lee K, et al.
Cancer Immunol Immunother
. 2022 Nov;
72(5):1233-1246.
PMID: 36385211
The development of new treatment agents in recent decades has significantly improved the survival of patients with multiple myeloma (MM). Nonetheless, MM remains an incurable disease; therefore, novel combination therapies...
6.
Jung E, Chu T, Vo M, Nguyen H, Lee D, Lee J, et al.
Cytotherapy
. 2022 Jul;
24(9):905-915.
PMID: 35778350
Background: The use of natural killer (NK) cells is a promising approach in the field of cancer immunotherapy; however, combination treatments are required to enhance the effects of NK cell...
7.
Chu T, Vo M, Lakshmi T, Ahn S, Kim M, Song G, et al.
Transl Oncol
. 2022 Apr;
20:101413.
PMID: 35413499
Dendritic cells (DCs) are the most potent antigen-presenting cells, and have thus been used in clinical cancer vaccines. However, the effects of DC vaccines are still limited, leading researchers to...
8.
Lakshmi Thangaraj J, Phan M, Kweon S, Kim J, Lee J, Hwang I, et al.
Cancer Immunol Immunother
. 2021 Jul;
71(3):613-625.
PMID: 34282497
Background: Natural killer (NK) cell-based immunotherapy is a promising treatment approach for multiple myeloma (MM), but obtaining a sufficient number of activated NK cells remains challenging. Here, we report an...
9.
Lakshmi Thangaraj J, Ahn S, Jung S, Vo M, Chu T, Phan M, et al.
Cell Mol Immunol
. 2021 May;
18(7):1652-1661.
PMID: 33980993
The use of natural killer (NK) cells is a promising and safe immunotherapeutic approach in the field of cancer immunotherapy. However, combination treatments are required to enhance the effector functions...
10.
Vo M, Ahn S, Chu T, Uthaman S, Pillarisetti S, Uong T, et al.
Cell Mol Immunol
. 2021 Mar;
18(6):1599-1601.
PMID: 33782574
No abstract available.